{"disease":{"id":"advanced-metastatic-clear-cell-renal-cell-carcinoma","name":"advanced metastatic clear cell renal cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01668784","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":821,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07383441","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":718,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05012371","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06863311","title":"Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Karie Runcie","has_results":false},{"nct_id":"NCT06942104","title":"Imaging of Solid Tumors Using 18F-TRX","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06866262","title":"Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT05361720","title":"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT01521715","title":"First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT06245915","title":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Arsenal Biosciences, Inc.","has_results":false},{"nct_id":"NCT07218692","title":"RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07128680","title":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05122546","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06399419","title":"CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Osel, Inc.","has_results":false},{"nct_id":"NCT07510334","title":"VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04904302","title":"Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01538238","title":"pazopanib_NCRCC,Ph2 STUDY","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03260504","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Washington","has_results":true}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}